uisitions, and, in general,
anticipated financial results for 2008. Actual performance and benefits
results may differ materially from those set forth in this press release
due to risks and uncertainties inherent in Digirad's business including,
without limitation, changes in business conditions, technology, customers'
business conditions, work force, suppliers, business prospects, economic
outlook, operational policy or structure, acceptance and use of Digirad's
camera systems and services, reliability, recalls, and other risks detailed
in Digirad's filings with the U.S. Securities and Exchange Commission,
including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form
8-K and other reports. Readers are cautioned to not place undue reliance on
these forward looking statements, which speak only as of the date hereof.
All forward looking statements are qualified in their entirety by this
cautionary statement, and Digirad undertakes no obligation to revise or
update the forward looking statements contained herein.
Digirad Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
(unaudited) (unaudited)
Revenues:
DIS $13,420 $11,606 $52,440 $49,614
Product 5,403 5,641 21,507 22,312
Total revenues 18,823 17,247 73,947 71,926
Cost of revenues:
DIS 10,749 8,595 39,520 37,675
Product 3,582 3,742 13,909 15,192
Total cost of revenues 14,331
'/>"/>
SOURCE Digirad Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy2.
Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation3.
DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results4.
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast5.
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology6.
DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call7.
Baxa Corporation Launches New Web Site8.
CuraGen Corporation Receives Notification from NASDAQ9.
Healionics Corporation Completes Series A Financing10.
Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 200811.
China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results